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PPARγ ligands inhibit the proliferation of non-small cell lung carcinoma (NSCLC) cells in vitro. The mechanisms responsible
for this eﬀect remain incompletely elucidated, but PPARγ ligands appear to inhibit the mammalian target of rapamycin (mTOR)
pathway. We set out to test the hypothesis that PPARγ ligands activate tuberous sclerosis complex-2 (TSC2), a tumor suppressor
gene that inhibits mTOR signaling. We found that the PPARγ ligand rosiglitazone stimulated the phosphorylation of TSC2 at
serine-1254, but not threonine-1462. However, an antagonist of PPARγ and PPARγ siRNA did not inhibit these eﬀects. Rosigli-
tazone also increased the phosphorylation of p38 MAPK, but inhibitors of p38 MAPK and its downstream signal MK2 had no
eﬀect on rosiglitazone-induced activation of TSC2. Activation of TSC2 resulted in downregulation of phosphorylated p70S6K, a
downstream target of mTOR. A TSC2 siRNA induced p70S6K phosphorylation at baseline and inhibited p70S6K downregulation
by rosiglitazone. When compared to a control siRNA in a thymidine incorporation assay, the TSC2 siRNA reduced the growth
inhibitory eﬀect of rosiglitazone by ﬁfty percent. These observations suggest that rosiglitazone inhibits NSCLC growth partially
through phosphorylation of TSC2 via PPARγ-independent pathways.
Copyright © 2007 ShouWei Han et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Lungcancerremainstheleadingcauseofcancer-relatedmor-
tality in the United States, and 30% to 40% of newly di-
agnosed patients with non-small cell lung cancer (NSCLC)
present with regionally advanced and unresectable stage III
disease [1]. Despite recent advances in understanding the
molecularbiologyoflungcarcinomaandtheintroductionof
multiple new chemotherapeutic agents for its treatment, the
poor ﬁve-year survival rate of less than 15% has not changed
substantially [2]. This justiﬁes the continuous search for
agents with therapeutic potential against NSCLC.
Peroxisome proliferator-activated receptors (PPARs; iso-
types α, β/δ, γ) are ligand-inducible nuclear transcription
factors that heterodimerize with retinoid X receptors and
bind to PPAR response elements (PPREs) located in the pro-
moter region of PPAR target genes [3]. These lipid-sensitive
receptors can be activated in a variable isotype-speciﬁc man-
ner by natural fatty acids, leukotrienes, prostaglandins, and
some synthetic agonists, including antidiabetic drugs such
as rosiglitazone, ciglitazone, and pioglitazone which are spe-
ciﬁc PPARγ ligands. These drugs are also eﬀective in reg-
ulating cell activation, diﬀerentiation, proliferation, and/or
apoptosis [4, 5]. The role of PPARγ, one PPAR isotype, has
beenextensivelystudiedthankstotheavailabilityofsynthetic
PPARγ agonists. The anticancer activity of PPARγ agonists
has been examined in a variety of cancers including colon,
breast, and prostate [6]. These and related studies support a
role for PPARγ as a potential tumor suppressor.
S e v e r a ls t u d i e sh a v ei m p l i c a t e dP P A R γ in lung cancer as
well. The expression of PPARγ has been demonstrated in
NSCLC and was correlated with tumor histological type and
grade [7]. Thus, it has been postulated that PPARγ mRNA
levels may serve as a prognostic marker in lung carcinoma
in addition to playing important roles in lung carcinogen-
esis. Activation of PPARγ by troglitazone, ciglitazone, and2 PPAR Research
pioglitazone caused growth inhibition and apoptosis of
NSCLC cells [8, 9]. Recently, studies in animal models of tu-
morigenesis showed that treatment of A549 tumor-bearing
SCID mice with troglitazone or pioglitazone inhibited pri-
mary tumor growth by 66.7%, and signiﬁcantly inhibited
the number of spontaneous lung metastasis lesions [10]. To-
gether, these observations suggest that PPARγ ligands may
serve as potential therapeutic agents in the management of
NSCLC, but the mechanisms responsible for these eﬀects re-
main incompletely elucidated.
We have reported that PPARγ agonists inhibit NSCLC
proliferation by inhibiting the mammalian target of rapam-
ycin (mTOR) signaling pathway through PPARγ-dependent
and -independent mechanisms [11]. The mTOR subfamily
belongs to the phosphatidylinositol 3-kinase (PI3-K)-related
kinase family and is partly inhibited by rapamycin, a feature
that has facilitated eﬀorts to study its function in eukaryotic
cells [12]. mTOR signaling induced by hormones, growth
factors, and amino acids regulates the phosphorylation of
several proteins including p70 ribosomal protein S6 kinase
(p70S6K) and eIF-4E binding protein (4E-BP1), which are
key regulators of translation, and are among the most well-
characterized targets of mTOR [12].
One of the downregulators of the mTOR pathway is the
tumor suppressor protein tuberous sclerosis complex (TSC).
TSC is composed of two proteins, TSC1 (also known as
hamartin) and TSC2 (known as tuberin), which function to
integrate growth factor and cell stress responses [13]. We set
out to explore the eﬀects of PPARγ agonists on TSC expres-
sion and the contribution of this pathway on inhibition of
cell proliferation in NSCLC cells treated with the PPARγ ag-
onist rosiglitazone. We found that PPARγ ligands activate
TSC2, which, in turn, inhibits mTOR signaling in NSCLC
cells through PPARγ-independent pathways.
2. MATERIALS AND METHODS
2.1. Cultureandchemicals
The human NSCLC cell line H2106 was obtained from the
American Type Culture Collection (Manassas, Va, USA)
and grown in RPMI-1640 medium supplemented with
10% heat-inactivated FBS, HEPES buﬀer, 50IU/mL peni-
cillin/streptomycin, and 1μg amphotericin (complete medi-
um) as previously described [14]. Polyclonal antibodies spe-
ciﬁc for TSC2, p38 MAPK, p70S6K, and their respective
phosphorylated active forms were purchased from Cell Sig-
naling (Beverly, Mass, USA). GW9662 was purchased from
Cayman Chemical Co. (Ann Arbor, Mich, USA). The in-
hibitor of the mitogen-activated protein kinase-activated
protein kinase 2 (MAPKAP kinase 2, MK2), a synthetic 13-
residue peptide (KKKALNRQLGVAA) corresponding to the
phosphorylation site of HSP27, one of the known substrates
of MK2, was purchased from Calbiochem (San Diego, Calif,
USA). Rosiglitazone, antibodies against PPARγ, SB239063,
and other chemicals were purchased from Sigma Aldrich (St.
Louis, Mo, USA) unless otherwise indicated.
2.2. WesternBlotanalysis
Western blotting was performed as previously described
[15]. Brieﬂy, protein concentrations were determined by the
Bio-Rad protein assay. Equal amounts of protein from whole
cell lysates were solubilized in 2x SDS-sample buﬀer and
separated on SDS-8% polyacrylamide gels. Blots were incu-
bated with antibodies raised against TSC2 and phosphory-
lated TSC2 (1:2000), p38 MAPK and phosphor-p38 MAPK,
p70S6K and phosphor-p70S6K (1:1000). The blots were
washed and followed by incubation with a secondary goat
antibody raised against rabbit IgG conjugated to horseradish
peroxidase (1:2000, Cell Signaling, Beverly, Mass, USA). The
blots were washed, transferred to freshly made ECL solution
(Amersham, Arlington, Ill, USA) for 1minute, and exposed
to X-ray ﬁlm. In controls, the antibodies were omitted or re-
placed with a control rabbit IgG.
2.3. TreatmentwithPPARγ andTSC2small
interferingRNA
The PPARγ (Cat number sc-29455) and TSC2 siRNAs (Cat
number sc-36762) and the control siRNA (Cat number
sc-37007) were purchased from Santa Cruz Biotechnology,
Inc. (Santa Cruz, Calif, USA). For the transfection pro-
cedure, cells were grown to 50% conﬂuence and PPARγ,
TSC2, or control siRNAs were transfected using the Lipofec-
tamine 2000 reagent (Invitrogen, Carlsbad, Calif, USA) ac-
cording to the manufacturer’s instructions. Brieﬂy, oligofec-
tamine reagent was incubated with serum-free medium for
10minutes.Subsequently,amixtureofsiRNAwasadded.Af-
ter incubation for 15minutes at room temperature, the mix-
ture was diluted with medium and added to each well. The
ﬁnal concentration of siRNA in each well was 100nM. After
culturing for 48hours, cells were washed and resuspended in
newculturemediainthepresenceorabsenceofrosiglitazone
for up to 48hours for Western blot and cell growth assays.
2.4. [Methyl-3H]thymidineincorporationassay
H2106 NSCLC cells (104 cells/well) were cultured with the
selective PPARγ antagonist GW9662 (20μM) for 1hour, or
transfected with TSC2 siRNA (100nM) for 48hours be-
fore exposing the cells to rosiglitazone (10μM) followed by
incubation with 1μCi/mL [methyl-3H] thymidine (Amer-
sham, speciﬁc activity 250Ci/mmol) for up to 48hours. The
medium was removed and the attached cells were washed
with 1x PBS. Afterwards, the attached cells were treated with
ice-cold 6% trichloroacetic acid (TCA) at 4◦Cf o r2 0m i n u t e s
and washed once with 6% TCA. The cells were then solubi-
lized with 0.1 N NaOH and counted in a liquid scintillation
counter in 4mL of scintillation ﬂuid.
2.5. Statisticalanalysis
All experiments were repeated a minimum of three times.
All data collectedfromWestern Blot and [Methyl-3H]-thym-
idine incorporation assays were expressed as means ±SD.
The data presented in some ﬁgures are from a representativeShouWei Han et al. 3
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Figure 1: Rosiglitazone stimulates the activation of TSC2. (a) Time-dependent eﬀect of rosiglitazone on TSC2 phosphorylation.C e l l u l a rp r o t e i n
was isolated from H2106 cells that were cultured with increasing concentrations of rosiglitazone (Rosig.) for 1hour followed by Western
blot analysis with antibodies against total TSC2 and phosphorylated TSC2 (p-TSC2). (b) Eﬀect of PPARγ antagonists on rosiglitazone-induced
TSC2 phosphorylation. Cellular protein was isolated from H2106 cells cultured for up to 2hours in the presence or absence of GW9662
(20μM) before exposure of cells to rosiglitazone (Rosig., 10μM) for an additional 24hours, then subjected to Western blot analysis for
total TSC2 and phosphorylated TSC2 (p-TSC2). (c) Eﬀect of PPARγ siRNA on rosiglitazone-induced TSC2 phosphorylation. H2106 cells were
t r a n s f e c t e dw i t hc o n t r o lo rP P A R γ siRNA (100nM each) for 48hours before exposing the cells to rosiglitazone (Rosig., 10μM) for up to
24hours. Afterwards, we performed Western blot analysis for total TSC2 and phosphorylated TSC2 (p-TSC2). Actin served as internal
control for normalization purposes (Con, indicates untreated control cells).
experiment, which was qualitatively similar in the replicate
experiments. Statistical signiﬁcance was determined with
Student’s t test (two-tailed) comparison between two groups
of data sets. Asterisks shown in the ﬁgures indicate signiﬁ-
cant diﬀerences of experimental groups in comparison with
the corresponding control condition (P<. 05, see ﬁgure leg-
ends).
3. RESULTS
3.1. Rosiglitazonestimulatestheexpression
ofTSC2protein
Since rosiglitazone has been found to regulate the PI3-
K/Akt/mTOR/p70S6K signaling pathway, we tested if it also
aﬀectedTSC2,anupstreamregulatorofthatpathway.H2106
cells treated with rosiglitazone for the indicated period of
time showed an increase in the phosphorylation of TSC2
at serine-1254, whereas only a slight increase in phospho-
rylation was detected on threonine-1462 (Figure 1(a)). To-
tal TSC2 protein levels remained unchanged. PPARγ ligands
have been shown to exert their eﬀects through pathways de-
pendent and independent of PPARγ. To test if phosphoryla-
tion of TSC2 by rosiglitazone was mediated through activa-
tion of PPARγ, cells were pretreated with a selective PPARγ
antagonist, GW9662, or PPARγ siRNA before exposing them
to rosiglitazone. As depicted in Figures 1(b) and 1(c), the
inhibitory eﬀect of rosiglitazone on the phosphorylation of
TSC2 was not aﬀected by GW9662 (b) or by PPARγ siRNA4 PPAR Research
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Figure 2: The role of p38 MAPK signaling cascade in mediating the eﬀect of rosiglitazone on activation of TSC2. (a) Time-dependent eﬀect of
rosiglitazone on phosphorylation of p38 MAPK. Cellular proteins were isolated from H2106 cells treated with rosiglitazone (Rosig., 10μM)
for the indicated time period. Afterwards, Western blot analyses were performed using a polyclonal antibody against phosphor-p38 MAPK
(Thr180/Tyr182)andtotalp38MAPK.Actinservedasinternalcontrolfornormalizationpurposes.(b)Eﬀectofp38inhibitoronrosiglitazone-
induced TSC2 phosphorylation. Cellular protein was isolated from H2106 cells cultured for up to 2hours in the presence or absence of
SB239063(10μM)beforeexposureofcellstorosiglitazone(Rosig.,10μM)foranadditional24hours,thensubjectedtoWesternblotanalysis
for total TSC2 and phosphorylated TSC2 (p-TSC2). Actin served as internal control for normalization purposes (Con, indicates untreated
control cells). (c) Eﬀect of MK2 inhibitor on rosiglitazone-induced TSC2 phosphorylation. Cellular protein was isolated from H2106 cells
cultured for up to 2hours in the presence or absence of MK2 inhibitor (10μM) before exposure of cells to rosiglitazone (Rosig., 10μM) for
an additional 24hours, then subjected to Western blot analysis for total TSC2 and phosphorylated TSC2 (p-TSC2). Actin served as internal
control for normalization purposes (Con, indicates untreated control cells).
(c)suggestingthatPPARγ-independentsignalsmediatedthis
eﬀect. Note that the PPARγ siRNA blocked PPARγ protein
production, while the control siRNA had no eﬀect (c).
3.1.1. Rosiglitazoneincreasesthephosphorylationof
p38MAPK,butblockadeofp38MAPKand
itsdownstreamsignalshadnoeffecton
rosiglitazone-inducedactivationofTSC2
PPARγ ligands have been shown to induce the activation of
p 3 8M A P Ki nd i ﬀerent cell systems [16, 17]. Activation of
p38mitogen-activatedproteinkinase(MAPK)anditsdown-
stream kinase MK2 have been associated with the phospho-
rylation of TSC2 [18]. Similarly, we found that rosiglita-
zone induced a transient increase in the phosphorylation of
p38 MAPK in a time-dependent manner with maximal in-
duction at 2hours (Figure 2(a)). We next assessed if acti-
vation of p38 signals were related to the eﬀect of rosigli-
tazone on TSC2 activation. As shown in Figures 2(b) and
2(c), SB239063, a selective p38 inhibitor, and KKKALNRQL-
GVAA, a potent and selective inhibitor of MK2, had no ef-
fectonrosiglitazone-inducedTSC2phosphorylation(serine-
1254). No eﬀects were noticed with increasing doses of these
inhibitors (not shown).
3.1.2. SilencingTSC2restoredthemTOR-relatedsignaland
partiallyblockedtheeffectofrosiglitazoneoncell
growthinhibition
We next examined if upregulation of TSC2 by rosiglitazone
was associated with inhibition of mTOR signaling as deter-ShouWei Han et al. 5
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Figure 3: Silencing TSC2 restored the activity of p70S6K. (a) TSC2 siRNA blocks TSC2 production. H2106 cells were transfected with control
or TSC2 siRNA (100nM each) for 30hours. Afterwards, we performed Western blot analysis for TSC2 proteins (Con, indicates untreated
cells). (b) TSC2 siRNA ameliorates the inhibitory eﬀect of rosiglitazone on p70S6K phosphorylation. H2106 cells were transfected with control
or TSC2 siRNA (100nM each) for 48hours before exposing the cells to rosiglitazone (Rosig., 10μM )f o ru pt o2 4h o u r s .A f t e r w a r d s ,w e
performed Western blot analysis for p70S6K proteins (Con, indicates untreated cells). The representative data shown here is obtained from
at least three separate experiments. Graphs are densitometry results. (∗indicates signiﬁcant diﬀerences as compared to the zero hour or
untreated cells (P<. 05); ∗∗indicates signiﬁcance of combination treatment as compared with rosiglitazone alone (P<. 05).)
mined by evaluating the phosphorylation state of p70S6K, a
downstream target of mTOR. To determine the exact contri-
bution of TSC2, we tested tumor cells transfected with con-
trol and TSC2 siRNAs. As shown in Figure 3(a), the TSC2
siRNA blocked TSC2 protein production, while the control
siRNAhadnoeﬀect.Armedwiththesetools,wetestedtheef-
fects of rosiglitazone on p70S6K. As expected, upregulation
of TSC2 by rosiglitazone coincided with downregulation of
phosphorylated p70S6K (Figure 3(b)). Silencing of TSC2 by
siRNA induced phosphorylation of p70S6K at baseline and
inhibited p70S6K downregulation in the presence of rosigli-
tazone demonstrating a direct link between TSC2 induction
and inhibition of mTOR signaling (Figure 3(b)).
3.2. Rosiglitazoneinhibitscarcinomacellproliferation
We next tested the contribution of TSC2 to NSCLC cell pro-
liferation in the setting of rosiglitazone treatment using an
[3H] thymidine incorporation assay. As expected, we found
that rosiglitazone inhibited NSCLC cell proliferation. This is
consistent with our own observations (not shown) and ﬁnd-
ings by others [10] showing inhibition of tumor growth in
vivo in response to rosiglitazone. Interestingly, silencing of
TSC2 reduced the growth inhibitory eﬀect of rosiglitazone
by approximately 50%, whereas a control siRNA had no ef-
fect (Figure 4).6 PPAR Research
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Figure 4: Silencing TSC2 partly blocked the eﬀect of resiglitazone
on cell growth inhibition. H2106 cells transfected with control or
TSC2 siRNA (100nM each) for 48hours before exposing the cells
to rosiglitazone (Rosig., 10μM) and incubated with 10μCi/mL
[methyl-3H] thymidine for 48hours. Afterwards, cell numbers were
determined. All data are depicted as means ± SD. (∗indicates sig-
niﬁcant diﬀerences as compared to the untreated cells (P<. 05);
∗∗indicates signiﬁcance of combination treatment as compared
with rosiglitazone (Rosig.) alone (P<. 05).)
4. DISCUSSION
Rosiglitazone, one of the thiazolidinedione derivatives, is the
most potent and selective synthetic ligand of PPARγ. It binds
to PPARγ with a kD of approximately 40nM and it is known
to have marked adipogenic eﬀects on preadipocyte and mes-
enchymal stem cells in vitro as well as dramatic antidiabetic
eﬀects [19]. However, not all of its cellular eﬀects are medi-
ated via PPARγ [20, 21]. Herein, we show that rosiglitazone
increasesPPARγ protein expression in NSCLCin a time- and
dose-dependent fashion. Note that the concentrations used
were consistent with those reported by others. For exam-
ple, Valentiner et al. found that rosiglitazone inhibited the
in vitro growth and viability of human neuroblastoma cell
lines in a dose-dependent manner showing considerable ef-
fects only at high concentrations (10μM and 100μM) [22].
In another study, rosiglitazone inhibited both the prolifer-
ation and invasiveness of the human adrenocortical cancer
cell line H295R in a dose-dependent manner with maximal
eﬀects (about 50% inhibition) noted at 20μM[ 23].
We previously demonstrated that rosiglitazone inhibited
the activation of the PI3-K/Akt/mTOR signaling pathway in
NSCLC cells [11] and, therefore, set out to explore the eﬀects
of rosiglitazone on modulators of this pathway. mTOR sig-
naling is induced by hormones, growth factors, and amino
acids, and regulates the phosphorylation of several proteins
including p70S6K and 4E-BP1, which are key regulators of
translation,andareamongstthemostwell-characterizedtar-
gets of mTOR [12]. A modulator of the mTOR pathway is
the tumor suppressor protein TSC2, which functions to inte-
grate growth factor and cell stress responses [13]. The TSC2
gene is known to be involved in mammalian cell cycle con-
trol and its overexpression is thought to exert an antitumor
eﬀect on cancer cells [24]. Here, we report that rosiglitazone
increased the phosphorylation of TSC2 highlighting the rel-
evance of this tumor suppressor in mediating the eﬀects of
rosiglitazone. However, this eﬀect appeared to be indepen-
dent of PPARγ since the inhibitor of PPARγ, GW9662, and
transfection with PPARγ siRNA had no eﬀect on this pro-
cess.
TSC2 is phosphorylated by multiple kinases, including
Akt, RSK1, ERK, CDC2, MK2, and AMPK. Therefore, TSC2
integrates signals from multiple signaling pathways and in-
ﬂuences cell growth through regulation of the mTOR path-
way [25]. Note that the rosiglitazone-induced phosphoryla-
tion of TSC2 occurred at serine-1254, but not at threonine-
1462 sites, which are sites diﬀerent from those phospho-
rylated by Akt and AMPK [26, 27]. The eﬀect of phos-
phorylation of TSC2 at serine-1254 site remains unclear
[25]. The interaction of TSC2 with 14-3-3 is associated with
phosphorylation of serine-1254 and may be independent of
Akt. However, TSC2 serine-1254 phosphorylation does not
necessarily inﬂuence TSC2–14-3-3 interactions [28]. On the
contrary, the association between 14-3-3 and TSC2 requires
phosphorylation of serine-1210, which is not considered an
Akt phosphorylation site [29]. This discrepancy may be due
to the diﬀerent cells studied and the elicitation of mech-
anisms other than those related to PI3-K, 14-3-3 and p38
pathways.Howthesemultiplephosphorylationeventsarein-
tegratedbyTSC2toregulatecellgrowthneedstobeexplored
further.
PPARγ ligands have been shown to induce the activa-
tion of p38 MAPK in diﬀerent cell systems [16, 17]. In line
with this, we showed that rosiglitazone increased the phos-
phorylation of p38 MAPK in NSCLC cells. Activation of p38
MAPK and its downstream signal MK2 have been associated
with phosphorylation of TSC2 (serine-1210) [18], and the
inhibitor of p38 MAPK reduced the phosphorylation of both
p38 MAPK and MK2 [30]. However, in the current study,
blockade of p38 MAPK and its downstream signal MK2 had
no eﬀect on rosiglitazone-induced TSC2 phosphorylation
suggesting that the p38 MAPK cascade plays no role in medi-
ating the eﬀect of rosiglitazone on TSC2. The concentrations
of these inhibitors were based on other studies which showed
signiﬁcantinhibitionofp38MAPKanditsdownstreamMK2
signaling cascade [30, 31].
TSC1-TSC2 complexes have recently been implicated in
cell survival responses. The molecular mechanisms by which
TSC2 aﬀects mTOR-related signals remain unclear. We
found that knockdown of TSC2 resulted in inhibition of
the eﬀect of rosiglitazone on the mTOR downstream target
p70S6KsuggestingaroleforTSC2inmediatingthiseﬀect.In
cellproliferationassays,weshowedthattheTSC2siRNApar-
tially restored NSCLC cell growth in the presence of rosigli-
tazone, although knockdown of TSC2 alone had no eﬀectShouWei Han et al. 7
on NSCLC cell proliferation. This suggests that TSC2 does
not contribute to NSCLC cell proliferation at baseline, but
its phosphorylation partially mediates the growth inhibitory
eﬀect of rosiglitazone.
Taken together, our results demonstrate that rosiglita-
zone inhibits NSCLC cell growth in part through activa-
tion of TSC2 with the consequent suppression of mTOR sig-
naling. This eﬀect appeared to be independent of PPARγ
and p38 MAPK signaling pathways. This work complements
our previous work demonstrating partial inhibition of the
mTOR pathway by rosiglitazone through downregulation of
Akt and induction of PTEN via PPARγ-dependent path-
ways [11]. Together, the activation of rosiglitazone-induced
PPARγ-dependent and -independent pathways results in in-
hibition of NSCLC growth. These observations are justifying
further work testing the use of rosiglitazone (and perhaps
other PPARγ ligands) as potential coadjuvants in the treat-
ment of NSCLC in humans.
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PPARγ: Peroxisome proliferator-activated
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